AU2013344796B2 - Use of IL-1 beta binding antibodies for treating peripheral arterial disease - Google Patents

Use of IL-1 beta binding antibodies for treating peripheral arterial disease Download PDF

Info

Publication number
AU2013344796B2
AU2013344796B2 AU2013344796A AU2013344796A AU2013344796B2 AU 2013344796 B2 AU2013344796 B2 AU 2013344796B2 AU 2013344796 A AU2013344796 A AU 2013344796A AU 2013344796 A AU2013344796 A AU 2013344796A AU 2013344796 B2 AU2013344796 B2 AU 2013344796B2
Authority
AU
Australia
Prior art keywords
subject
canakinumab
seq
months
binding antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013344796A
Other languages
English (en)
Other versions
AU2013344796A1 (en
Inventor
Craig BASSON
Mark Fishman
Shi Yin Foo
Tom Thuren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2013344796A1 publication Critical patent/AU2013344796A1/en
Application granted granted Critical
Publication of AU2013344796B2 publication Critical patent/AU2013344796B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2013344796A 2012-11-16 2013-11-14 Use of IL-1 beta binding antibodies for treating peripheral arterial disease Ceased AU2013344796B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727334P 2012-11-16 2012-11-16
US61/727,334 2012-11-16
PCT/US2013/070042 WO2014078502A1 (en) 2012-11-16 2013-11-14 Use of il-1 beta binding antibodies for treating peripheral arterial disease

Publications (2)

Publication Number Publication Date
AU2013344796A1 AU2013344796A1 (en) 2015-05-07
AU2013344796B2 true AU2013344796B2 (en) 2016-11-10

Family

ID=49679654

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013344796A Ceased AU2013344796B2 (en) 2012-11-16 2013-11-14 Use of IL-1 beta binding antibodies for treating peripheral arterial disease

Country Status (6)

Country Link
US (4) US10000565B2 (enExample)
EP (1) EP2919811B1 (enExample)
JP (1) JP2016502526A (enExample)
AU (1) AU2013344796B2 (enExample)
CA (1) CA2891556A1 (enExample)
WO (1) WO2014078502A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180291097A1 (en) * 2015-06-04 2018-10-11 Craig Basson Use of il-1 beta binding antibodies to treat peripheral arterial disease
AU2016272900A1 (en) 2015-06-04 2017-12-07 Novartis Ag Use of IL-1 beta binding antibodies to treat peripheral arterial disease
WO2017021294A1 (en) 2015-07-31 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Antibody variants
MX387420B (es) * 2015-11-24 2025-03-18 Commw Scient Ind Res Org Producción de virus en cultivos celulares.
WO2018015897A1 (en) * 2016-07-21 2018-01-25 Novartis Ag Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112256A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
KR20200052331A (ko) * 2017-09-13 2020-05-14 노파르티스 아게 알코올성 간염의 치료를 위한 il-1b 결합 항체의 용도
KR102880762B1 (ko) * 2018-09-20 2025-11-03 에스에프제이 파마 엑스, 인코포레이티드 티카그렐러 활성을 반전시키는 방법
CN116726362A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN112402359A (zh) * 2020-11-04 2021-02-26 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077145A2 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
WO2009149189A2 (en) * 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2009149185A2 (en) * 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2010028275A1 (en) * 2008-09-05 2010-03-11 Xoma Technology Ltd. METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES
WO2010138939A1 (en) * 2009-05-29 2010-12-02 Xoma Technology Ltd. CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF
WO2011047266A1 (en) * 2009-10-15 2011-04-21 Abbott Laboratories Il-1 binding proteins
WO2012018790A2 (en) * 2010-08-03 2012-02-09 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
WO2009120307A2 (en) 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
PE20120586A1 (es) * 2009-01-29 2012-06-17 Abbott Lab Proteinas de union a il-1
BR112014007253A2 (pt) 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077145A2 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
WO2009149189A2 (en) * 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2009149185A2 (en) * 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2010028275A1 (en) * 2008-09-05 2010-03-11 Xoma Technology Ltd. METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES
WO2010138939A1 (en) * 2009-05-29 2010-12-02 Xoma Technology Ltd. CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF
WO2011047266A1 (en) * 2009-10-15 2011-04-21 Abbott Laboratories Il-1 binding proteins
WO2012018790A2 (en) * 2010-08-03 2012-02-09 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof

Also Published As

Publication number Publication date
CA2891556A1 (en) 2014-05-22
US20210317202A1 (en) 2021-10-14
EP2919811B1 (en) 2018-12-26
US20160326243A1 (en) 2016-11-10
EP2919811A1 (en) 2015-09-23
JP2016502526A (ja) 2016-01-28
US20180258166A1 (en) 2018-09-13
WO2014078502A1 (en) 2014-05-22
US10000565B2 (en) 2018-06-19
US20200148759A1 (en) 2020-05-14
AU2013344796A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
AU2013344796B2 (en) Use of IL-1 beta binding antibodies for treating peripheral arterial disease
US12465635B2 (en) Methods of treating inflammatory arthritis using secukinumab
US20250051428A1 (en) Antibodies to amyloid beta
US10975145B2 (en) Methods of reducing the risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered a qualifying CV event
US20230265182A1 (en) Use of il-1 beta binding antibodies to treat peripheral arterial disease
MD3439689T2 (ro) Metode de tratament al hiperlipidemiei cu un inhibitor al ANGPTL8 și un inhibitor al ANGPTL3
AU2024202601A1 (en) Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
JP2025516723A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法
WO2015083120A1 (en) USE OF IL-1β BINDING ANTIBODIES
US20180291097A1 (en) Use of il-1 beta binding antibodies to treat peripheral arterial disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired